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1 Improved anticoagulation control reduces hemorrhagic and thromboembolic event rates. 2, 3 Many studies have shown that such event rates are higher when patients' INRs are outside the therapeutic range. [4] [5] [6] [7] [8] [9] [10] [11] A study that systematically measures the proportion of hemorrhages and thromboemboli that occur when INRs are above and below the therapeutic range, respectively, will help both physicians and policy-makers gauge the potential effect of improved anticoagulation control. In our investigation, we measured and analyzed these proportions.
Methods
We identified pertinent citations in English in the MEDLINE and EMBASE (1980 EMBASE ( -2006 databases using the search strategy outlined in Appendix 1. This strategy combined medical subject headings and keywords related to anticoagulation (e.g., anticoagulants, warfarin) and to hemorrhages and thromboemboli (e.g., cerebrovascular accident, bleed). We retrieved the full text of articles for further review if the title or abstract suggested that patients taking anticoagulants were studied and data on hemorrhages or thromboemboli were reported. Studies were included in our review if the majority of patients taking anticoagulants orally had an INR range with a lower limit between 1.8 and 2 and an upper limit between 3 and 3.5, and the INR at the time of the hemorrhagic or thromboembolic event was recorded; these limits represent the most common therapeutic ranges for patients taking oral anticoagulants. All citations and studies were reviewed for inclusion by a single author (N.O.). We considered all major hemorrhages (i.e., those that required hospital admission, a transfusion or surgery, or that reduced hemoglobin levels by ≥ 20 g/L) and thromboemboli (stroke, myocardial infarction, venous thromboembolism or systemic emboli, confirmed by objective tests). We excluded patient groups taking anticoagulants by mouth with concomitant antiplatelet therapy, because their risk of hemorrhagic and thromboembolic events is considerably higher than the risks of patients taking anticoagulants alone.
12,13
From each study, we abstracted the total number of major hemorrhages and thromboemboli that could be assigned to particular INR ranges. Some studies assigned events to INRs based on measurements taken at the time of the event or at hospital admission, whereas others used measurements made beforehand to approximate the INR at the time of the event. We grouped the events into 3 INR ranges: below, Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Background: Patients taking anticoagulants orally over the long term have international normalized ratios (INRs) outside the individual therapeutic range more than one-third of the time. Improved anticoagulation control will reduce hemorrhagic and thromboembolic event rates. To gauge the potential effect of improved anticoagulation control, we undertook to determine the proportion of anticoagulant-associated events that occur when INRs are outside the therapeutic range.
Methods:
We conducted a meta-analysis of all studies that assigned hemorrhagic and thromboembolic events in patients taking anticoagulants to discrete INR ranges. We identified studies using the MEDLINE and EMBASE databases. We included studies reported in English if the majority of patients taking oral anticoagulants had an INR range with a lower limit between 1.8 and 2 and an upper limit between 3 and 3.5, and their INR at the time of the hemorrhagic or thromboembolic event was recorded.
Results:
The final analysis included results from 45 studies (23 that reported both hemorrhages and thromboemboli; 14 that reported hemorrhages only; and 8, thromboemboli only) involving a median of 208 patients (limits of interquartile range [25th-75th percentile] 131-523 subjects; total n = 71 065). Of these studies, 64% were conducted at community practices; the remainder, at anticoagulation clinics. About 69% of the studies were classed as having moderate or high quality. Overall, 44% (95% confidence interval [CI] 39%-49%) of hemorrhages occurred when INRs were above the therapeutic range, and 48% (95% CI 41%-55%) of thromboemboli took place when below it. The mean proportion of events that occurred while the patient's INR was outside the therapeutic range was greater for studies with a short mean follow-up (< 1 yr). Between-study heterogeneity was significant (p < 0.001).
Interpretation: Improved anticoagulation control could decrease the likelihood of almost half of all anticoagulantassociated adverse events. within and above the therapeutic range. For each study, we then calculated the proportion of major hemorrhages that occurred when INRs exceeded the therapeutic range and the proportion of thromboemboli when INRs fell below it.
We used a random effects model to pool individual study estimates into an overall mean proportion of hemorrhages that occurred above therapeutic range and overall mean proportion of thromboemboli that occurred below therapeutic range. In both models, individual studies were weighted by the inverse of their variance. 14 We used linear regression models to explain betweenstudy heterogeneity by determining if the proportion of events that occurred when INRs were outside the therapeutic range was associated with study-level factors, including mean patient age, mean follow-up time, study setting, target INR range, type of anticoagulant used (e.g., warfarin, acenocoumarol, phenprocoumon) and study quality. We measured study quality using key study design components suggested by the MOOSE Group 15 and presented in the NewcastleOttawa Scale. 16 These components included the external validity of the study cohort, appropriateness of outcome assessment, and adequacy of follow-up. We classified studies as high quality if they included patients who represented the average user of anticoagulants taken by mouth, used blind evaluation or record linkage to assess events, and either reported a complete follow-up or provided a description of patients lost to follow-up; as moderate quality, if 2 of these 3 criteria were satisfied; and all others as low quality. We generated all linear regression models in SAS software using its GLM (general linear models) Procedure, with individual studies weighted by the inverse of variance. We stratified the meta-analyses by all factors that were significantly associated (p < 0.05) with the proportion of events occurring outside therapeutic range.
Finally, we also determined if the proportion of hemorrhagic or thromboembolic events occurring above or below the therapeutic INR range was associated with the proportion of overall time spent outside the range by abstracting the proportion of time spent above and below the therapeutic range from each study. We investigated this association using linear regression models, as described in the preceding paragraph.
Results
The literature search yielded 3220 citations, of which 362 articles were retrieved and reviewed. We excluded studies that did not monitor patients within the appropriate INR range (n = 29) and studies that did not assign events to particular INR ranges (n = 288).
The final analysis included results from 45 studies: 23 that reported both hemorrhages and thromboemboli; 14 that reported hemorrhages only; 4,7,40-51 and 8, thromboemboli only.
8,9,52-57 The studies included a median of 208 patients (limits of interquartile range [25th-75th percentile] 131-523 subjects; total n = 71 065). About two-thirds of the studies (64%) were conducted at community practices; the remainder, at anticoagulation clinics. Study quality was classed as being moderate or high in 69%. Most studies (70%) involved patients with various conditions requiring anticoagulant drugs. Only 9% of the studies did not use blind assessment or record linkage to assess hemorrhagic or thromboembolic events. Half of the studies reported a complete follow-up. It is noteworthy that one-third of studies did not assign all of the events recorded to particular INR ranges. Also, 13 studies (29%) utilized a previous INR measurement, taken 2-30 days before the actual hemorrhagic or thromboembolic event, to approximate the INR at the time of the event.
Overall, 44% (95% confidence interval [CI] 39%-49%) of hemorrhages occurred at INRs above the therapeutic range, whereas 48% (95% CI 41%-55%) of thromboemboli occurred at INRs below therapeutic range ( Fig. 1 and Fig. 2) . However, the regression models found that mean follow-up time was the only study-level factor that was significantly associated with the proportion of events that occurred outside the therapeutic INR range. Therefore, the meta-analyses were stratified by mean follow-up time: less than or exceeding 1 year. Studies with a mean follow-up time of less than 1 year had a greater proportion of events at extreme INRs ( Fig. 1 and Fig. 2 ), although these proportions did not differ significantly from studies with a longer follow-up time.
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Both meta-analyses noted significant between-study heterogeneity (p < 0.001).
Twenty-one of the included studies (47%) reported the proportion of total observation time along with either hemorrhages occurring above the therapeutic INR range (18 studies, 4,17-29,40-43 40%) or thromboemboli occurring below it (16 studies,
8,17-29,52,53 36%). The proportion of time spent with INRs below the therapeutic range in each study was significantly associated with the proportion of thromboemboli occurring below range (p < 0.05). Studies in which patients spent more time with INRs below the therapeutic range had a significantly higher proportion of thromboembolic events below range. Proportion of time spent above range was not, however, significantly associated with the proportion of hemorrhages occurring at INR levels above the therapeutic range.
Interpretation
We found that about half of all hemorrhages occur above and half of all thromboemboli occur below the therapeutic range for INR. Mean study length of follow-up was associated with the proportion of events that occur outside the therapeutic range. We also found that the proportion of thromboemboli occurring at INRs below the therapeutic range was greater with increased time spent at INRs below the range.
Although half of all anticoagulation events occurred at INRs outside the therapeutic range, we believe it equally notable that half of all events did not. Other factors, such as patient age and comorbidities, may be contributing to these events. [59] [60] [61] [62] It is also noteworthy that, of the half of all events associated with anticoagulants taken orally that occurred outside the therapeutic range, not all would have been avoided with perfect anticoagulation quality. Knowledge of the population-attributable risk is required to estimate the effect of improved anticoagulation on event rates. 63 Our review found that shorter mean follow-up time was associated with a greater proportion of events outside range. This could be due to incident patients having worse anticoagulation control than prevalent users. 64 To account for this difference in patients across studies, we stratified the metaanalyses by a mean follow-up cut-off of 1 year. Despite this, significant heterogeneity persisted between the studies. This is not surprising, since heterogeneity is high when results from observational studies are pooled. 65 Moreover, the statistical power to explain heterogeneity by means of study-level variables was limited. More information about patient-level factors associated with the proportion of time spent with the patient within the therapeutic INR range 66 would likely better explain heterogeneity between studies.
We found that the proportion of thromboemboli occurring below therapeutic range was significantly greater when time spent below range increased. This result reinforces the findings of Veeger and colleagues, 2 who reported signifi- cantly higher rates of thromboembolic events with increased time spent outside the therapeutic INR range. Unlike Veeger's group, however, we did not find that the proportion of hemorrhages occurring above range increased with the proportion of time spent above range. Our study is important because it systematically measured the proportion of hemorrhages and thromboemboli that occur when INRs are above and below the therapeutic range, respectively. Our results should encourage physicians and policy makers to evaluate and implement interventions, such as anticoagulation clinics 1, 67 and patient self-management, 68, 69 that improve anticoagulation control.
Our study is not without limitations. Studies may have been missed despite our comprehensive search. The number of events assigned to INR levels in studies may be biased, since one-third of the studies did not assign all of the events to INR ranges and 28% of the studies used previously measured INRs to approximate the level of anticoagulation at the time of the events. Studies reported slight variations of target therapeutic range. And finally, we were unable to examine the difference in the proportion of events that occurred outside the therapeutic INR range by anticoagulation indication, because more than half of the studies included patients with different indications for taking anticoagulants. (ideally with individual patient data) is required to determine if the proportion of anticoagulant-associated events that occur outside the therapeutic range of INRs varies with indication for anticoagulant use.
In conclusion, we found that improved anticoagulation control could decrease the likelihood of almost half of all adverse events associated with anticoagulants taken orally.
